Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
An in sitro assay to predict primary resistance to PD-1 blockade.
Trends Mol. Med. 27, 297-298 (2021)
Immune check point inhibition (ICI) is a paradigm shift in oncology, but most patients treated with ICI will not respond to treatment. Thus, the need for predictive biomarkers for ICI is high. Dubuisson and colleagues have now reported on a new functional assay that might accurately inform on ICI response.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Review
Schlagwörter
Cancer Immunology ; Immune Check Point Inhibition ; Immuno-oncology ; In Sitro
ISSN (print) / ISBN
1471-4914
e-ISSN
1471-499X
Zeitschrift
Trends in Molecular Medicine
Quellenangaben
Band: 27,
Heft: 4,
Seiten: 297-298
Verlag
Elsevier
Verlagsort
The Boulevard, Langford Lane, Kidlington, Oxford Ox5 1gb, Oxon, England
Nichtpatentliteratur
Publikationen
Begutachtungsstatus
Peer reviewed
Institut(e)
Unit for Clinical Pharmacology (KKG-EKLiP)
Förderungen
Melanoma Research Alliance
Hector foundation
International Doctoral Program i-Target: Immunotargeting of Cancer - Elite Network of Bavaria
German Cancer Aid
ErnstJung-Stiftung
LMU Munich's Institutional Strategy LMUexcellent
Bundesministerium fur Bildung und Forschung Project Onkattract
European Research Council
German Research Foundation
Deutsche Jose-Carreras Leukamie-Stiftung
Marie-SklodowskaCurie ProgramTraining Network for the Immunotherapy of Cancer - H2020 Program of the European Union
Hector foundation
International Doctoral Program i-Target: Immunotargeting of Cancer - Elite Network of Bavaria
German Cancer Aid
ErnstJung-Stiftung
LMU Munich's Institutional Strategy LMUexcellent
Bundesministerium fur Bildung und Forschung Project Onkattract
European Research Council
German Research Foundation
Deutsche Jose-Carreras Leukamie-Stiftung
Marie-SklodowskaCurie ProgramTraining Network for the Immunotherapy of Cancer - H2020 Program of the European Union